Soru

Zorluk: OrtaPulmonary and Critical Care

A 71-year-old man presents to the pulmonary clinic reporting a 9-month history of progressively worsening shortness of breath and a dry, hacking cough. He denies fever, chills, orthopnea, paroxysmal nocturnal dyspnea, or chest pain. His past medical history is significant for hypertension and a 35-pack-year smoking history, having quit 10 years ago. Current medications include lisinopril and amlodipine.

Vital signs show a pulse of 86/min, respiratory rate of 22/min, blood pressure of 128/78 mm Hg, and oxygen saturation of 91% on room air. Physical examination reveals digital clubbing. Pulmonary auscultation demonstrates fine, end-inspiratory "Velcro-like" crackles predominantly at the lung bases bilaterally. Cardiac examination is normal with no murmurs, gallops, or jugular venous distention. There is no lower extremity edema.

Pulmonary function testing (PFT) reveals the following:

ParameterPatient Value% Predicted
FEV1FEV_11.9 L65%
FVCFVC2.2 L58%
FEV1/FVCFEV_1/FVC86%N/A
TLCTLC3.8 L56%
DLCODLCO11.5 mL/min/mm Hg48%

High-resolution computed tomography (HRCT) of the chest shows bilateral, subpleural reticular opacities with traction bronchiectasis and honeycombing.

Based on the clinical presentation and diagnostic findings, which of the following are accurate regarding this patient's condition? (Select all that apply)

  1. Initiation of antifibrotic therapy with pirfenidone or nintedanib is indicated to slow the decline in pulmonary function.Cevap
  2. The patient's arterial blood gas on room air is likely to show a widened alveolar-arterial (A−aA-a) oxygen gradient.Cevap
  3. C
    The physical examination findings represent left ventricular volume overload, and daily loop diuretics are the primary indicated therapy.
  4. D
    If the patient's arterial PaCO2PaCO_2 is 3030 mm Hg, a normal compensatory response would result in an elevated serum bicarbonate level.
  5. E
    Broad-spectrum empiric antibiotic therapy should be initiated immediately to treat a presumed infectious etiology for his chronic cough.

Cevap

The correct statements are that antifibrotic therapy (pirfenidone or nintedanib) is indicated to slow disease progression, and the patient is expected to have a widened alveolar-arterial (A-a) oxygen gradient.
The patient's presentation, restrictive PFTs (normal/elevated FEV1/FVCFEV_1/FVC, low TLCTLC), severely reduced DLCODLCO, and HRCT findings of subpleural honeycombing are virtually pathognomonic for idiopathic pulmonary fibrosis (IPF). The destruction of the alveolar-capillary membrane causes a significant diffusion limitation and V/Q mismatch, resulting in hypoxemia and a widened alveolar-arterial (A−aA-a) oxygen gradient. Pirfenidone and nintedanib are FDA-approved antifibrotic agents that have been shown to slow the rate of forced vital capacity (FVCFVC) decline in patients with IPF.

Adım Adım Çözüm

1
Interpret the clinical presentation and physical exam.
The patient has a 9-month history of progressive dyspnea, dry cough, digital clubbing, and fine "Velcro-like" basilar crackles.
These are classic signs of interstitial lung disease, highly suspicious for idiopathic pulmonary fibrosis (IPF) in an older adult male.
2
Analyze the PFT and HRCT data.
A normal/high FEV1/FVC ratio (>80%) with decreased FVC and TLC indicates a restrictive defect. The severely decreased DLCO indicates impaired gas exchange. HRCT shows classic honeycombing.
This confirms the diagnosis of idiopathic pulmonary fibrosis (IPF) exhibiting the usual interstitial pneumonia (UIP) pattern, ruling out obstructive disease or purely cardiac causes.
3
Determine appropriate management and expected physiological findings.
Antifibrotic drugs are the standard of care to slow FVC decline. Diffusion impairment leads directly to a widened A-a gradient and hypoxemia.
These elements address the specific pathophysiology and current evidence-based management for IPF.

Anahtar Kavram

Diagnosis, pathophysiology, and management of Idiopathic Pulmonary Fibrosis (IPF).
Bu soruyu puanla